Dermatology
Case Report
Hyperkeratosis lenticularis perstans (Flegel’s Disease) – Lack of Response to Treatment with Tacalcitol and CalcipotriolBlaheta H.-J. · Metzler G. · Rassner G. · Garbe C.Department of Dermatology, Eberhard Karl University, Tübingen, Germany
|
|
Dermatology 2001;202:255–258
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
* The final prices may differ from the prices shown due to specifics of VAT rules.
Article / Publication Details
First-Page Preview
Published online: May 23, 2001
Issue release date: 2001
Number of Print Pages: 4
Number of Figures: 3
Number of Tables: 0
ISSN: 1018-8665 (Print)
eISSN: 1421-9832 (Online)
For additional information: https://www.karger.com/DRM
Abstract
Hyperkeratosis lenticularis perstans (HLP) or Flegel’s disease is a rare dermatosis characterized by asymptomatic hyperkeratotic papules predominantly located on the lower extremities. Lesional and non-lesional epidermis samples were studied by light- and electron-microscopic examination. The main ultrastructural finding was the presence of structurally altered Odland bodies/membrane-coating granules. Different therapeutic options for HLP have been reported, but none of the treatments was shown to be consistently effective. Here, we report on a patient with Flegel’s disease who did respond to topical 5-fluorouracil, whereas topical vitamin D3 synthetics were ineffective.
© 2001 S. Karger AG, Basel
Related Articles:
References
-
Flegel H: Hyperkeratosis lenticularis perstans. Hautarzt 1958;9:362–364.
- Li TH, Hsu CK, Chiu HC, Chang CH: Multiple asymptomatic hyperkeratotic papules on the the lower part of the legs – Hyperkeratosis lenticularis perstans (HLP) (Flegel disease). Arch Dermatol 1997;133:910.
- Langer K, Zonzits E, Konrad K: Hyperkeratosis lenticularis perstans (Flegel’s disease): Ultrastructural study of lesional and perilesional skin and therapeutic trial of topical tretinoin versus 5-fluorouracil. J Am Acad Dermatol 1992;27:812–816.
- Buchner SA: Hyperkeratosis lenticularis perstans (Flegel’s disease): In situ characterization of T cell subsets and Langerhans’ cells. Acta Derm Venereol 1988;68:341–345.
- Kanitakis J, Hermier C, Hokayem D, Schmitt D: Hyperkeratosis lenticularis perstans (Flegel’s disease): A light and electron microscopic study of involved and uninvolved epidermis. Dermatologica 1987;174:96–101.
- Pearson LH, Smith JGJ, Chalker DK: Hyperkeratosis lenticularis perstans (Flegel’s disease): Case report and literature review. J Am Acad Dermatol 1987;16:190–195.
- Kuokkanen K, Alavaikko M, Pitkanen R: Hyperkeratosis lenticularis perstans (Flegel’s disease). Acta Derm Venereol 1983;63:357–360.
- Frenk E, Tapernoux B: Hyperkeratosis lenticularis perstans (Flegel): A biological model for keratinization occurring in the absence of Odland bodies? Dermatologica 1976;153:253–262.
- van de Staak WJ, Bergers AM, Bongaarts P: Hyperkeratosis lenticularis perstans (Flegel). Dermatologica 1980;161:340–346.
-
Lever WF, Schaumburg-Lever G: Histopathology of the skin; in Lever WF, Schaumburg-Lever G (eds): Histopathology of the Skin. Philadelphia, Lippincott, 1983.
- Jang KA, Choi JH, Sung KJ, Moon KC, Koh JK: Hyperkeratosis lenticularis perstans (Flegel’s disease): Histologic, immunohistochemical, and ultrastructural features in a case. Am J Dermatopathol 1999;21:395–398.
- Miranda Romero A, Sambucety PS, del Pozo CB, Fernandez MM, Gomez JIE, Munoz MG: Unilateral hyperkeratosis lenticularis perstans (Flegel’s disease). J Am Acad Dermatol 1998;39:655–657.
- Schaumburg LG: The alkaline phosphatase anti-alkaline phosphatase technique in dermatopathology. J Cutan Pathol 1987;14:6–9.
- Bean SF: Hyperkeratosis lenticularis perstans: A clinical, histopathologic, and genetic study. Arch Dermatol 1969;99:705–709.
- Price ML, Jones EW, MacDonald DM: A clinicopathological study of Flegel’s disease (hyperkeratosis lenticularis perstans). Br J Dermatol 1987;116:681–691.
- Ikai K, Murai T, Oguchi M, Takigawa M, Komura J, Ofuji S: An ultrastructural study of the epidermis in hyperkeratosis lenticularis perstans. Acta Derm Venereol 1978;58:363–365.
- Metze D, Lubke D, Luger T: Hyperkeratosis lenticularis perstans (Flegel’s disease) – A complex disorder of epidermal differentiation with good response to a synthetic vitamin D3 derivate. Hautarzt 2000;51:31–35.
- Tezuka T: Dyskeratotic process of hyperkeratosis lenticularis perstans (Flegel): The abnormal formation of cystine-rich protein. Dermatologica 1982;164: 379–385.
- Tidman MJ, Price ML, MacDonald DM: Lamellar bodies in hyperkeratosis lenticularis perstans. J Cutan Pathol 1987;14:207–211.
- Elias PM, Williams ML: Neutral lipid storage disease with ichthyosis: Defective lamellar body contents and intracellular dispersion. Arch Dermatol 1985;121:1000–1008.
- Duschet P, Schwarz T, Gschnait F, Luger A: Hyperkeratosis lenticularis perstans (Flegel’s disease). Hautarzt 1985;36:299–301.
- Lindemayr H, Jurecka W: Retinoid acid in the treatment of hyperkeratosis lenticularis perstans Flegel. Acta Derm Venereol 1982;62:89–91.
-
Wilson PD, Ive FA: Treatment of hyperkeratosis lenticularis perstans (Flegel) with topical fluorouracil. Dermatologica 1980; 60:337–340.
- Cooper SM, George S: Flegel’s disease treated with psoralen ultraviolet A. Br J Dermatol 2000;142:340–342.
Article / Publication Details
First-Page Preview
Published online: May 23, 2001
Issue release date: 2001
Number of Print Pages: 4
Number of Figures: 3
Number of Tables: 0
ISSN: 1018-8665 (Print)
eISSN: 1421-9832 (Online)
For additional information: https://www.karger.com/DRM
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
